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Abstract
Purpose Androgen deprivation therapy (ADT) is a treatment used in men with prostate cancer (PCa); however it is responsible
for many adverse effects, with negative impact on quality of life. ADT causes loss of bone mineral density (BMD) and skeletal
muscle mass, alteration of body composition, and cognitive function, which altogether lead to increased risk of accidental falls
and fractures. This systematic review analyses the effectiveness of physical exercise (PE) in preventing accidental falls and
fractures and reducing the loss of BMD in men with PCa receiving ADT.
Methods We searched MEDLINE, EMBASE, CINAHL, and the Cochrane Library for articles between database inception and
September 2, 2020. Eligible studies included randomized controlled trials (RCTs) investigating the effects of exercise on bone
health in men with PCa receiving ADT.
Results Nine RCTs were included. Experimental PE consisted in multicomponent programmes that involved aerobic, resistance,
impact-loading exercise, and football training. None of the RCTs investigated the risk of accidental falls and fractures, while two
trials reported beneficial effects of PE on lumbar spine, hip, and femoral shaft BMD. No further significant difference was
detected in the outcomes investigated.
Conclusion Evidence of the effectiveness of PE to prevent the risk of accidental falls and fractures and BMD loss is lacking.
Nevertheless, clinical guidelines recommend PE as a part of the clinical management of men with PCa receiving ADT due to its
known numerous health benefits. Research should focus on PE strategies to prevent accidental falls, a clinically relevant outcome
in this vulnerable population.
Trial registration The study protocol was registered with International Prospective Register of Systematic Reviews
(PROSPERO, number CRD 42020158444) on 04/28/2020.
Keywords Prostatic neoplasms . Exercise . Accidental falls . Fractures, bone . Physical therapymodalities . Prevention
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Introduction
Prostate cancer (PCa) is the most prevalent cancer among men
worldwide, with 3.724.658 cases in 2018 [1].
Androgen deprivation therapy (ADT) is currently the stan-
dard systemic treatment in patients with metastatic or more
aggressive PCa [2]. Often, ADT is used in combination with
radiotherapy for localized advanced PCa with the aim to in-
crease survival and control disease progression [2].
However, ADT is responsible for many adverse effects,
with negative impact on quality of life [3]. Apart from the
increased risk for cardiovascular events and metabolic syn-
drome [4, 5], ADT also alters the body composition, with loss
in skeletal muscle mass that leads to a decrease in muscle
strength [6, 7]. Also, patients onADTmanifest significant loss
of bonemineral density (BMD), which occurs especially with-
in the first year of treatment [8] and is associated with higher
osteoporosis rates and risk of fractures [9]. Moreover, ADT
seems responsible for cognitive dysfunction, although this
finding has not been completely clarified and needs further
investigation [10].
It is known that both reduction in muscle strength and
cognitive dysfunction are predictors of higher fall rates and
hospitalization in older adults [11, 12]. Thus, considering the
loss of BMD, altogether these side effects of ADT explain the
increased risk of accidental falls and fractures in this popula-
tion [13].
In elderly adults, physical exercise (PE) has been proposed
in different modalities as a strategy to produce several health
benefits [14]. Recent guidelines addressing elderly adults rec-
ommend multicomponent exercise programmes, including re-
sistance and neuromotor exercises, as a strategy to reduce the
risk of accidental falls [14] as PE can prevent osteoporosis and
improves body composition, muscle strength, and cognitive
function [14]. Moderate-vigorous intensity programmes that
include balance exercises seem to be particularly effective to
reduce the risk of accidental falls [14].
Initial evidence indicates that in patients with cancer, PE
may produce numerous benefits on physical performance,
quality of life, and cancer-related fatigue [15]. In patients with
PCa receiving ADT, exercise is beneficial to body composi-
tion, muscle strength, and physical performance [16–18],
while its effects on bone health, cardiometabolic risk, quality
of life, and cognitive functions remain uncertain [19, 20].
Patients receiving ADT are more exposed to the risk of
accidental falls and fractures [9] due to the side effects of this
drugs. As PE is recommended in healthy elderly adults to
prevent these risks and also to prevent bone loss, we hypoth-
esized that PE could be effective in preventing accidental falls
and fractures even in men with PCa receiving ADT.
Furthermore, recent evidence suggests PE as strategy to pre-
vent osteoporosis inmen receiving ADTwhen associatedwith
pharmacological therapy [21]. Thus, we conducted this
systematic review to search for evidence of the effectiveness
of exercise on bone health in this population. Specifically, we
searched for randomized controlled trials that implemented PE
programmes to prevent accidental falls and fractures and/or to
prevent the loss of BMD, in patients with PCa treated with
ADT.
Methods
This systematic review followed the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
guidelines [22]. The study protocol was registered with
International Prospective Register of Systematic Reviews
(PROSPERO, number CRD 42020158444).
Search strategy and selection criteria
A systematic review of the literature was performed through
sequential, individualized searches in MEDLINE, EMBASE,
CINAHL, and the Cochrane Library. We searched for studies
published up to September 2, 2020, without filters for study
design or language. The search terms and strategies used are
reported in online resource 1. Duplicates were removed in
EndNote (version X7.5). Also, we performed a manual search
in the reference lists of the studies included in this review to
find any other relevant citation that may have been missed by
the electronic search.
We included randomized controlled trials (RCTs) investi-
gating the effects of supervised or unsupervised exercise on
bone health in adult individuals with PCa receiving ADT.
Studies were eligible if the experimental intervention
consisted of structured PE programmes compared with standard
care or placebo active control. When exercise was associated
with dietary supplements, studies were included if the exercise
was clearly the predominant part of the experimental interven-
tion. Furthermore, studies were eligible if they investigated the
number of accidental falls or fractures that occurred in a specific
timeframe or if they reported data on bone density by dual-
energyX-ray absorptiometry (DEXA). Studies focusing on gen-
eralized advice and education on the benefit of exercise or stud-
ies that collected data on pathological (and not accidental) frac-
tures were excluded.
Data analysis
Two investigators (B.B., M.C.) screened the title and abstract of
all the citations retrieved to check their appropriateness related to
the purpose of this review. The investigators also retrieved and
checked for eligibility the full texts of studies deemed appropri-
ate. Then, two investigators (B.B., S.C.) assessed the eligible
studies for their methodological quality according to the
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Cochrane risk-of-bias tool [23]. In the whole process, any dis-
agreement was resolved by discussion and consensus.
Two investigators (B.B., M.C.) extracted the following da-
ta from studies included: authors, year and country, sample
size and average age, exclusion criteria, bone outcome mea-
sures collected and follow-up duration, general characteristics
of the experimental intervention and standard care, drop-out
rate. When essential data were missing, the investigators re-
quested them from authors (at least three attempts).
Results
Bibliographic search results
The electronic search yielded 304 citations, duplications ex-
cluded. One more citation was retrieved through the manual
search, for a total of 305. According to the screening of title
and abstract, 269 citations were excluded because they did not
focus on the topic under investigation.
Thirty-six full texts were reviewed for eligibility, 27 of
which were excluded for the following reasons: three confer-
ence abstracts and six study protocols referred to published
full texts already retrieved [24–31]; four studies did not meet
inclusion criteria with respect to the outcome, as onemeasured
only pathological fractures [32], and the others did not report
data on bone health [31, 33, 34]; one study did not test a
structured physical exercise intervention, focusing instead on
patient education [35]; two studies compared different struc-
tured physical exercise interventions, without comparison to
standard care [36, 37]. Finally, eleven studies were also ex-
cluded since they reported insufficient data for analysis [38] or
were protocols of ongoing studies [39–48]. We contacted the
corresponding authors in order to obtain preliminary results
(minimum three attempts), but the ones who replied said they
had no data to share yet.
Thus, nine published full texts met the inclusion criteria
and contributed their data to this review [24–30, 49, 50].
These full texts accounted for eight study designs, as the two
by Uth et al. [28, 29] reported data collected at the 3- and 8-
month follow-up, respectively, of the same study design and
sample (Fig. 1). Of note, the study by Bjerre et al. [30] includ-
ed patients with PCa regardless of their treatment with ADT.
However, they reported specific data for the subgroup of pa-
tients on ADT and these data were considered in this review.
Risk of bias of the included studies
The Cochrane risk-of-bias analysis of the included studies is
reported in Fig. 2. Two studies did not report sufficient infor-
mation to assess the adequacy of the random sequence gener-
ation [28, 29, 49, 51]. Due to the nature of the intervention,
seven of the nine included studies did not provide blinding to
group assignment for both participants and personnel [24–30,
49]. Moreover, four studies did not report enough information
to judge blinding of outcome [24–26, 49]. Nevertheless, all
the included studies were judged at low risk of detection bias
since outcome measures were frequently objective. The ana-
lytical assessment of the risk of bias for each study included is
reported in online resource 2.
Study characteristics
Table 1 summarizes the characteristics of the studies included
in this review. All were RCTs published in the last decade in
different continents [24–30, 49, 50]. All studies allowed for
the recruitment of patients treated at several specialized
hospitals.
One study was a three-armed RCT comparing two active
interventions with one control [25]. For the purposes of this
review, we considered both the comparisons. Two studies
were cross-over designs, and, for this review, we considered
data of the first follow-up, before the cross-over, which was
scheduled at 6 months for both studies [25, 26].
A high drop-out rate (≥ 28%) was registered in two studies
[29, 49] and equal to 20% in a further one [50], whereas one
study did not report this data point for the subgroup of patients
receiving ADT [30]. The safety of interventions was assessed
by recording the number and type of adverse events. Only two
trials reported adverse events related to exercise [27, 28]: one
partial Achilles tendon rupture [28], two fibula fractures [28],
and five minor musculoskeletal injuries [27, 28]. Other trials
registered generic health issues not related to the PE interven-
tion that occurred both in the experimental and in the control
group, such as hospitalization (n = 22) [25–27, 29, 49, 50],
injury/accident (n = 10) [25–27], death (n = 4) [25, 49], and
others (n = 4) [24, 26–29]. Bjerre et al. [30] analysed safety
outcomes as number of falls, fractures, and serious adverse
events occurring even in the subgroup of patients receiving
ADT (respectively n = 5, n = 1, and n = 4), without any further
detailed classification.
Participants
The sample size of the eight RCTs selected in this review
ranged from 51 to 154 individuals, for a total of 625 partici-
pants, of whom 351 were randomized to receive experimental
PE and 274 were randomized to receive standard care. The
sample was made up of males aged from 66.0 to 70.8 years
with local or metastatic PCa receiving ADT.
All the study designs excluded patients with restrictions to
PE based on specific assessments (e.g., inability to walk
400 m [24–26], VO2 max < 35 ml/kg/min [28, 29], pain in
the metastatic site associated to activity [28, 29]) or based on
clinicians’ judgement [24–27, 30, 49, 50]. Five studies also
excluded patients with musculoskeletal, cardiovascular, and
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neurological disorders that could inhibit them from exercising
[24–29] or patients with contraindications to unsupervised
exercise [50]. Further exclusion criteria have been summa-
rized in detail in Table 1.
Characteristics of control group intervention and the
experimental group intervention
Table 2 summarizes the characteristics of standard care and
experimental PE programmes.
The control group intervention consisted of stretching ac-
tivities [49, 50] or educational material [25, 30, 50] or simply
in encouraging patients to maintain their usual level of phys-
ical activity [27–29]. Taaffe et al. [26] provided all partici-
pants with standard daily supplementation of calcium
(1000 mg/day) and vitamin D3 (800 IU/day).
Experimental PE interventions were characterized by mul-
ticomponent programmes [24–26, 28–30, 49, 50], with only
one exception that implemented a single component of PE
[27]. In most cases, PE consisted in aerobic exercise (AE) that
could also be performed as weight-bearing activities and that
was associated with resistance exercise (RE) [24–26, 50] and
with impact-loading exercise (IE) [26]. Two study designs
implemented football training (FT) as experimental PE
[28–30]; although the full texts did not report this type of
training in detail, it is likely that, by its nature, it included
AE and IE, among others (e.g., RE, stretching).
Most experimental interventions were performed in 1-hour
sessions repeated two or three times a week [24–30, 49]. Most
of the studies described how the PE components were pro-
gressively modulated in terms of intensity, volume, and type
of exercise [24–27, 49, 50]. Although the intensity of FT was
not defined, this type of intervention was implemented
through an initial warm-up followed by 2 matches lasting
15/20 min [28–30]. Uth et al. [28, 29] progressively increased
the number of matches and the frequency of sessions per
week.
Experimental PE were implemented as supervised exercise
in clinics [24–26] or in sports facilities [28–30], as a combi-
nation of supervised and unsupervised (home-based) sessions
[25, 27, 49], or as unsupervised home-based PE only [50].
Bone outcomes
Accidental falls and fractures
None of the studies selected for this review was designed to
analyse the risk of accidental falls and/or fractures as an
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Fig. 1 PRISMA flow chart of
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outcome measure of the effectiveness of experimental PE in
reducing those risks. All study designs measured adverse
events [24–30, 49, 50]. The two studies that tested FT also
recorded fractures occurring during this kind of intervention to
judge its safety due to the increased risk of collisions with
other players and falls [28–30]. Although this was not the
outcome we were interested in, we underline that all the
experimented PE programmes were deemed safe [24–30, 49,
50].
Of note, several studies secondarily collected data on phys-
ical function through heterogeneous tests (e.g., Flamingo bal-
ance test, sit-to-stand test, etc.) [24, 27–29, 50]. The proof of
effectiveness of experimental PE was demonstrated through
the sit-to-stand test [24, 27, 50], which is valid to measure
muscle power of the lower limbs; its validity in predicting
accidental falls and fractures in patients with cancer, however,
must still be demonstrated [52].
BMD
Table 3 reports the results of between-group comparisons of
BMD at the various anatomical sites.
All the RCTs selected for this review reported data on bone
density measured by DEXA at different anatomical sites
(Table 3). Lumbar spine BMD was collected in all the includ-
ed studies, while femoral neck BMDwas analysed in seven of
them [24, 25, 27, 29, 30, 49, 50]. At the 6-month follow-up,
Newton et al. [25] recorded a significant difference between
groups for lumbar spine BMD (mean change 0.014 g/cm2,
95% CI 0.001–0.027, p = 0.039) and a positive trend for fem-
oral neck BMD (mean change 0.010 g/cm2, 95% CI 0.000–
0.020, p = 0.050), in favour of the experimental resistance and
impact-loading PE compared with control group. No further
significant difference was detected by any of the studies in
these outcome measures. Of note, a per-protocol analysis per-
formed by Winters-Stone et al. [49] at the level of single
lumbar vertebra reported a significant difference in BMD only
for L4 (p = 0.03), in favour of experimental PE.
Total hip BMD was measured by seven study designs
[25–27, 29, 30, 49, 50], with significant differences recorded
only by Uth et al. [29] on both hips at the 8-month follow-up
(right 0.015 g/cm2, 95% CI 0.003–0.027, p = 0.015; left
0.017 g/cm2, 95% CI 0.002–0.032, p = 0.030). This study
was the only one that collected data on BMD at the femoral
shaft of both legs, recording a difference in favour of experi-
mental PE on both sides (right 0.018 g/cm2, 95% CI 0.004–
0.032, p = 0.016; left 0.024 g/cm2, 95% CI 0.005–0.044, p =
0.015) [29].
No further statistically significant difference was registered
for BMD at any further anatomical site examined, such as
whole body [24–28, 30], trochanter [25, 27, 49], or legs [28].
Considering the almost total absence of data in favour of
PE with respect to this outcome, which was collected in var-
ious anatomical sites, we deemed it inappropriate to carry out
a meta-analysis.
Further results: bone turnover markers
Six study designs also assessed several bone turnover markers
(BTMs) such as markers of bone formation (alkaline phospha-
tase, procollagen type 1 amino-terminal propeptide and
osteocalcin) or markers of bone resorption (C-terminal
telopeptide of type I collagen, N-terminal telopeptide of type
I collagen) [24–26, 28, 29, 49, 50].
At the 3-month follow-up, Uth et al. [28, 29] registered a
statistically significant difference in favour of experimental
PE for the markers of bone formation procollagen type 1
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amino-terminal propeptide (36.6 μg/L, 95% CI 10.4–62.8,
p = 0.008) and osteocalcin (8.6 μg/L, 95% CI 3.3–13.8, p =
0.002), but this result was not confirmed at the subsequent 8-
month follow-up.
Discussion
The aim of this systematic review was to summarize the evi-
dence regarding the effectiveness of PE programmes in reduc-
ing the risk of accidental falls and fractures, as a clinically
relevant outcome in the PCa patient population.
Despite the strong existing evidence proving accelerated
bone loss, additional muscle weakness, and cognitive dys-
function caused by ADT [7, 10] and the benefits of PE in
reducing the risk of accidental falls in the healthy elderly pop-
ulation [14], no study has investigated the effects of exercise
on these clinically relevant endpoints in PCa patients.
Furthermore, the effectiveness of PE in lessening or
preventing the loss of BMD in this population is still uncertain
due to the inconsistent results yielded by this systematic re-
view. In particular, only two studies suggested that multicom-
ponent PE, in particular resistance and impact-loading exer-
cise or football training, may help achieve this outcome [25,
29]. These positive results could be explained by the longer
period of training [25], as a minimum of 6–8 months is re-
quired to achieve bone remodelling [53], or by the high num-
ber of accelerations and decelerations and change of direction
typically observed during the football training [29]. These
characteristics of the PE intervention could provide sufficient
bone-loading forces and osteogenic stimulus. However, both
these study designs were affected by a certain degree of risk of
bias. Therefore, although BMD was measured objectively,
their results should be interpreted with caution.
Thus, to date, evidence of the beneficial effects of PE on
bone health in men with PCa treated with ADT is still lacking,
even though PE is beneficial in the healthy elderly for the
same outcome [14].
The incidence of osteoporotic fractures increases with age,
and it is estimated that more than 8.9 million osteoporotic
fractures occur annually worldwide [54, 55]. In men over
the age of 75, the most frequent site of fracture is the hip,
the principal risk factor being low BMD [56]. Moreover, more
than 30% of community-dwelling older adults over the age of
75 fall every year [57], leading to fractures, hospitalizations,
and admission to nursing homes [58].
Therefore, the risk of falls in older adults increases mor-
bidity, mortality, and financial burden for societies [59].
Indeed, the costs associated with fragility fractures account
for €37 billion/year in Europe and are expected to increase
[54], whereas in the USA, the overall number of healthy
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Considering the progressive aging of the population, recent
guidelines suggest that future research should identify individ-
uals at increased risk of fracture, to whom fracture prevention
strategies should be targeted [61] in order to contain the in-
crease in costs associated with this event [62]. We think that
patients with PCa receiving ADT are among those individuals
because the side effects they have affect bone and lead to
double the healthcare cost per person [63]. Moreover, as fall
prevention programmes are recommended to the elderly in
general, as community-dwelling adults with cancer have
Table 3 Between-group comparisons for BMD
Follow-up (months) BMD outcome Mean change between groups (g/cm2) 95% CI p value
Cormie et al. (2015) [24] 3 Whole body − 0.002* − 0.013 to 0.009 0.692
Lumbar spine − 0.009* − 0.029 to 0.012 0.410
Femoral neck 0.000* − 0.025 to 0.024 0.987
Newton et al. (2019) [25] 6 (RE+IE) Whole body 0.005* − 0.002 to 0.011 0.174
Total hip 0.007* − 0.002 to 0.016 0.128
Lumbar spine 0.014* 0.001 to 0.027 0.039
Femoral neck 0.010* 0.000 to 0.020 0.050
Trochanter − 0.003* − 0.010 to 0.004 0.449
6 (AE+RE) Whole body 0.003* − 0.007 to 0.0012 0.614
Total hip 0.001* − 0.009 to 0.011 0.807
Lumbar spine 0.004* − 0.009 to 0.017 0.525
Femoral neck − 0.003* − 0.014 to 0.008 0.571
Trochanter − 0.002* − 0.01 to 0.007 0.699
Taaffe et al. (2019) [26] 6 Whole body NR NR 0.827
Total hip NR NR 0.848
Lumbar spine NR NR 0.111
Nilsen et al. (2015) [27] 4 Whole body 0.00* − 0.02 to 0.01 0.520
Total hip 0.00* − 0.01 to 0.01 0.690
Total lumbar spine 0.00* − 0.02 to 0.01 0.847
Femoral neck 0.00* − 0.02 to 0.01 0.467
Trochanter 0.00* − 0.01 to 0.00 0.221
Uth et al. (2016) [28] 3 Whole body 0.01 − 0.00 to 0.01 0.188
Legs 0.00 − 0.00 to 0.01 0.336
Uth et al. (2016) [29] 8 Total hip R: 0.015 0.003 to 0.027 0.015
L: 0.017 0.002 to 0.032 0.030
Lumbar spine 0.028 − 0.010 to 0.065 0.144
Femoral neck R: 0.015 − 0.002 to 0.031 0.078
L: 0.015 − 0.01 to 0.032 0.072
Femoral shaft R: 0.018 0.004 to 0.032 0.016
L: 0.024 0·005 to 0·044 0.015
Bjerre et al. (2019) [30] 6 Whole body 0.005 − 0.007 to 0.017 0.40
Total hip − 0.009* − 0.033 to 0.014 0.43
Lumbar spine 0.0017* − 0.019 to 0.053 0.34
Femoral neck 0.007* − 0.009 to 0.023 0.39
Winters-Stone et al. (2014) [49] 12 Total hip NR NR 0.37
Lumbar spine NR NR 0.47
Femoral neck NR NR 0.77
Greater trochanter NR NR 0.58
Kim et al. (2018) [50] 6 Total hip NR NR 0.727
Lumbar spine NR NR 0.756
Femoral neck NR NR 0.888
AE aerobic exercise, BMD bone mineral density,CI confidence intervals, IE impact-loading exercise, L left,NR not reported, R right, RE resistance exercise
*Analyses adjusted for baseline values
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greater accidental fall rates than do healthy elderly individuals
and as patients undergoing active treatment are even more at
risk [64], it seems logical to expect that the beneficial effects
of PE would be greater in patients with PCa receiving ADT
compared with healthy elderly individuals.
However, this systematic review demonstrated an almost
complete lack of studies supporting this. Not only have clin-
ically relevant outcomes never been investigated but also few
of the RCTs included were powered to detect the effects of PE
on BMD [25, 26, 49, 50].
We must say, however, that our review was limited to
collecting evidence on PE. As we did not consider other types
of interventions, such as nutritional and educational
programmes that could help to prevent accidental falls and frac-
tures, we cannot rule out that an evidence-based intervention
different from stand-alone PE could be successfully applied.
Furthermore, ten protocols of ongoing studies were retrieved
by our search strategy; it is therefore very likely that in the next
few years the conclusion drawn today, thanks to this extensive
review conducted with rigorous methodology, will be outdated.
A final consideration regards the type of PE programmes
tested in the studies included in this review: most combined
different exercise modalities, such as resistance, weight-
bearing endurance, and impact loading exercises, as recom-
mended to provide benefits to bone health [53]. Moreover,
PE programmes were of moderate-high intensity in all
cases, suggesting that, according to the evidence and exper-
tise, low-impact exercise may have no effect on BMD [53].
Despite this, the PE programmes did not produce the de-
sired result on bone mass. This may be due to the insuffi-
cient power of some of the included studies, or it may be
due to poor adherence to treatment, which is always an
issue in studies involving lifestyle changes [65]. Poor ad-
herence to treatment means that the expected dose of exer-
cise is not achieved by participants. Thus, it can be difficult
to determine the effect of the exercise on the outcomes of
interest. It could also be that, however intense the pro-
gramme, PE may not be sufficient to counteract the loss
of bone mass induced by aging and ADT.
Thus, to conclude, experts recommend exercise as part of
the treatment regimen of patients with cancer thanks to its
large number of health benefits [19]. This review suggests that
there is still no strong evidence to support this choice to pre-
vent bone density loss in patients with PCa receiving ADT,
according to recent literature [16, 21]. However, since exer-
cise is an effective strategy to produce a large number of
health benefits, future research should investigate the effects
of PE to prevent the risk of accidental falls in this population,
which is a clinically relevant outcome. For this purpose, PE
should include coordination and balance exercises as well as
muscle-strengthening activities. Evidence is needed regarding
more precise training components, dose, and progression of
exercise to prevent falls.
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